|May 8, 2014|
|06:08 EDT||MNK||Mallinckrodt reports Q2 adjusted EPS 95c, consensus 77c|
Reports Q2 revenue $557.8M, consensus $566.08M; Restructuring charges were $21.7 million for the second quarter of fiscal 2014, compared with $6.4 million in the prior-year period. The increase primarily reflects activities that will improve both cost of sales and SG&A under the previously announced $100 million to $125 million restructuring program.
News For MNK From The Last 14 Days
Check below for free stories on MNK the last two weeks.
|September 16, 2014|
|07:30 EDT||MNK||CRT Capital to hold a conference|
2nd Annual Investor Conference to be held in Greenwich, CT on September 16.
|September 4, 2014|
|09:02 EDT||MNK||Mallinckrodt announces MNK-155 Phase 3 efficacy trial met primary endpoint|
Mallinckrodt reported that a Phase 3 efficacy trial of investigational MNK-155 met the study’s primary endpoint of improved pain scores vs. placebo over the first 48 hours following bunionectomy. This difference in pain scores was statistically significant in favor of MNK-155. The data is being presented at PAINWeek 2014 on September 2-6. In addition to the Phase 3 study, Mallinckrodt will present data at PAINWeek from several other MNK-155 trials, including the pharmacokinetics, safety and subjective effects of abuse-related characteristics.
|September 3, 2014|
|09:07 EDT||MNK||Mallinckrodt reported MNK-155 HAL study data |
Subscribe for More Information
|07:53 EDT||MNK||Mallinckrodt management to meet with Deutsche Bank|
Meeting to be held in New York on September 3 hosted by Deutsche Bank.